Tevogen (TVGN) Assets Average (2022 - 2026)
Tevogen's (TVGN) quarterly Assets Average came in at $4.7 million in Q1 2026, up 23.48% on a YoY basis from $3.8 million in Q1 2025, and up 4.81% quarter-over-quarter from $4.4 million in Q4 2025.
Analysis
Tevogen (TVGN) Assets Average (2022 - 2026) Analysis & Trends
Tevogen (TVGN) has reported Assets Average for 5 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 23.48% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $4.7 million (up 23.48% YoY), and the FY2025 full-year result was $3.9 million, down 12.52% from the prior year.
- Assets Average improved to $4.7 million in Q1 2026 per TVGN's latest filing, from $4.4 million in the prior quarter.
- Across five years, Assets Average topped out at $355.8 million in Q4 2022 and bottomed at $3.3 million in Q2 2024.
- Historically, Assets Average has averaged $100.7 million across 5 years, with a median of $4.7 million in 2026.
- The sharpest annual moves came in 2024 and 2025: Assets Average sank 97.68% in 2024, then gained 25.0% in 2025.
- Over 5 years, Assets Average stood at $355.8 million in 2022, then sank by 95.52% to $16.0 million in 2023, then sank by 75.71% to $3.9 million in 2024, then grew by 14.52% to $4.4 million in 2025, then grew by 4.81% to $4.7 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $4.7 million, $4.4 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 1.45 Bn |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 2.69 Bn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 920.60 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 1.67 Bn |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 881.90 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 1.43 Bn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 154.46 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 3.18 Bn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 494.25 Mn |
| 10 | Tevogen | 27.76 Mn | 27.76 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 4.65 Mn |
| Dec 31, 2025 | 4.44 Mn |
| Sep 30, 2025 | 4.38 Mn |
| Jun 30, 2025 | 4.17 Mn |
| Mar 31, 2025 | 3.77 Mn |
| Dec 31, 2024 | 3.88 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Mar 31, 2024 | 4.43 Mn |
| Dec 31, 2023 | 15.96 Mn |
| Sep 30, 2023 | 26.39 Mn |
| Jun 30, 2023 | 25.92 Mn |
| Mar 31, 2023 | 191.30 Mn |
| Dec 31, 2022 | 355.84 Mn |
| Sep 30, 2022 | 353.76 Mn |
| Jun 30, 2022 | 352.90 Mn |
| Mar 31, 2022 | 352.84 Mn |